ReviewCurrent radiopharmaceuticals2020
FDG PET/CT in the Staging of Lung Cancer.
Review in Current radiopharmaceuticals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- [Frontiers in medicine · 2024Pooled it
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Evaluation of the Systemic Immune-Inflammation Index, Neutrophil-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio in Patients Diagnosed with Lung Cancer by Bronchoscopy in Relation to Disease Stage and PET/CT SUVmax.World journal of nuclear medicine · 2026Article
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
- Article
- The Role of 18F-FDG PET/CT in Monitoring Immunotherapy Response in Non-Small Cell Lung Cancer: Current Evidence and Challenges: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Accuracy of DOTATATE-positron emission tomography for preoperative nodal staging of carcinoid tumors of the lung.JTCVS open · 2025Article
- A Comprehensive Review on the Application of Artificial Intelligence for Predicting Postsurgical Recurrence Risk in Early-Stage Non-Small Cell Lung Cancer Using Computed Tomography, Positron Emission Tomography, and Clinical Data.Journal of medical radiation sciences · 2025Review
- Flexible Bronchoscopy and Non-Small-Cell Lung Cancer Staging: A Narrative Review of Modern Techniques for Optimized Clinical Decision-Making.Journal of clinical medicine · 2025Review
- The Emerging Roles of Metabolic Reprogramming in Non-Small Cell Lung Cancer Progression.Frontiers in bioscience (Landmark edition) · 2025Review
- Prognostic significance of total metabolic tumor volume on baseline 18 F-FDG PET/CT in patients with lung adenocarcinoma: further stratification of the ninth edition of TNM staging subgroups.Nuclear medicine communications · 2025Article
- F-18 FDG PET/CT Clinical Service Trends in Korea from 2018 to 2022: A National Surveillance Study.Nuclear medicine and molecular imaging · 2025Article
- Current and Future Applications of PET Radiomics in Radiation Oncology.PET clinics · 2025Review
- Article
- Evaluation of the efficacy ofFrontiers in oncology · 2025Article
- Real-World Data on Stage III Non-Small Cell Lung Cancer in Vietnam.Oncology research · 2025Article
- Predicting response and survival to first-line treatment with baseline [Therapeutic advances in medical oncology · 2025Article
- Advancements in Cancer Care by Exploring Multimodality Imaging Techniques and their Applications.Current medical imaging · 2025Review
- Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.Biomarkers in medicine · 2025Article
- Uncertainty-aware automatic TNM staging classification for [BMC medical informatics and decision making · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate staging is crucial for the proper management of patients with nonsmall cell lung cancer, especially for choosing the best treatment strategy. Different Imaging methods are used to stage patients with non-small cell lung cancer. In the last two decades, FDG PET/CT is carried out in almost all the main Hospitals around the world in this setting.
objectiveThe aim of this paper is to focus on the value of integrated FDG PET/CT in the TNM staging of the non-small cell lung cancer.
methodsA non-systematic revision of the literature was performed in order to identify all papers about the role of FDG PET/CT in the evaluation of non-small cell lung cancer and to highlight the value of FDG PET/CT in this setting.
resultsMany data are now available about this topic, including also randomized controlled trials. FDG PET/CT is of limited added value in the characterization of T status but it increases the diagnostic accuracy for the assessment of the nodal status. The main advantage of FDG PET/CT over conventional imaging methods is its higher sensitivity in identifying extra-thoracic metastases, especially bone and adrenal lesions.
conclusionPET/CT with FDG should be included in the diagnostic work-up of patients with lung cancer, because it provides useful information for appropriate therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.